86604-86-6

Basic information

• Product Name: 2-Chloro-6-(trifluoromethyl)-1H-benzimidazole
• Synonyms: 2-CHLORO-5-(TRIFLUOROMETHYL)BENZIMIDAZOLE;2-CHLORO-6-TRIFLUOROMETHYL-1H-BENZIMIDAZOLE;2-chloro-5-(trifluoromethyl)-1H-benzo[d]imidazole;2-chloro-6-(trifluoromethyl)-1H-benzo[d]imidazole;2-chloro-5-(trifluoroMethyl)-1H-1,3-benzodiazole;1H-BenziMidazole, 2-chloro-6-(trifluoroMethyl)-;2-Chloro-6-(trifluoroMethyl)benziMidazole;-Chloro-6-(trifluoromethyl)benzimidazole
• CAS NO: 86604-86-6
• Molecular Formula: C₈H₄ClF₃N₂
• Molecular Weight: 220.58
• Mol File: 86604-86-6.mol

Chemical Properties

• Melting Point: 186-188 °C
• Boiling Point: 322.1 °C at 760 mmHg
• Flash Point: 148.6 °C
• Appearance: /
• Density: 1.569 g/cm³
• Vapor Pressure: 0.000286mmHg at 25°C
• Refractive Index: 1.575
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 8.75±0.10(Predicted)
• CAS DataBase Reference: 2-Chloro-6-(trifluoromethyl)-1H-benzimidazole(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Chloro-6-(trifluoromethyl)-1H-benzimidazole(86604-86-6)
• EPA Substance Registry System: 2-Chloro-6-(trifluoromethyl)-1H-benzimidazole(86604-86-6)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 86604-86-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-Chloro-6-(trifluoromethyl)-1H-benzimidazole is used as a reagent for preparing chiral 2-aminobenzimidazoles, which serve as recoverable organocatalysts. These organocatalysts are valuable in the synthesis of enantioselective pharmaceutical compounds, contributing to the development of more efficient and environmentally friendly synthetic routes.
Used in Organic Synthesis:
In the field of organic synthesis, 2-Chloro-6-(trifluoromethyl)-1H-benzimidazole is utilized as a building block for the creation of complex organic molecules. Its unique structural features allow it to participate in various chemical reactions, facilitating the synthesis of target molecules with specific properties and functions.

InChI:InChI=1/C8H4ClF3N2/c9-7-13-5-2-1-4(8(10,11)12)3-6(5)14-7/h1-3H,(H,13,14)

Upstream product

• 530-62-1 1,1'-carbonyldiimidazole 
• 368-71-8 4-(trifluoromethyl)-1,2-phenylenediamine 
• 133687-93-1 5-(trifluoromethyl)-1,3-dihydro-2H-benzoimidazol-2-one 

Downstream Products

• 1170773-36-0 (1R,2R)-N₁-{6-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl}cyclohexane-1,2-diamine 
• 1073558-62-9 3-phenyl-8-[5-(trifluoromethyl)-1H-benzimidazol-2-yl]-1-oxa-3,8-diazaspiro-[4.5]decan-2-one 
• 1073558-69-6 3-(3,4-dichlorophenyl)-8-[5-(trifluoromethyl)-1H-benzimidazol-2-yl]-1-oxa-3,8-diazaspiro-[4.5]decan-2-one 
• 1453097-16-9 3-methyl-4-(phenylmethyl)-1-(5-trifluoromethyl-1H-benzimidazol-2-yl)-1H-pyrazol-5-ol 
• 1049799-23-6 C₂₀H₁₃ClF₃N₃O 

Relevant articles and documents

Synthesis and in Vitro Activity of Polyhalogenated 2-phenylbenzimidazoles as a New Class of anti-MRSA and Anti-VRE Agents

A series of novel polyhalogenated 2-phenylbenzimidazoles have been synthesized and evaluated for in vitro antistaphylococcal activity against drug-resistant bacterial strains (methicillin-resistant Staphylococcus aureus, and vancomycin-resistant Enterococcus faecium. Certain compounds inhibit bacterial growth perfectly. 11 was active than vancomycin (0.78 μg/mL) with the lowest MIC values with 0.19 μg/mL against methicillin-resistant Staphylococcus aureus, 8 and 35 exhibited best inhibitory activity against vancomycin-resistant Enterococcus faecium (1.56 μg/mL). The mechanism of action for this class of compounds appears to be different than clinically used antibiotics. These polyhalogenated benzimidazoles have potential for further investigation as a new class of potent anti-methicillin-resistant Staphylococcus aureus and anti-vancomycin-resistant Enterococcus faecium agents.

ISOINDOLINES AS HDAC INHIBITORS

The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs), having the formula: (I) wherein Z, X1, X2, Y1, Y2, Y3, L, Z, and R are described herein.

Discovery of a Selective Aurora A Kinase Inhibitor by Virtual Screening

Here we report the discovery of a selective inhibitor of Aurora A, a key regulator of cell division and potential anticancer target. We used the atom category extended ligand overlap score (xLOS), a 3D ligand-based virtual screening method recently developed in our group, to select 437 shape and pharmacophore analogs of reference kinase inhibitors. Biochemical screening uncovered two inhibitor series with scaffolds unprecedented among kinase inhibitors. One of them was successfully optimized by structure-based design to a potent Aurora A inhibitor (IC50 = 2 nM) with very high kinome selectivity for Aurora kinases. This inhibitor locks Aurora A in an inactive conformation and disrupts binding to its activator protein TPX2, which impairs Aurora A localization at the mitotic spindle and induces cell division defects. This phenotype can be rescued by inhibitor-resistant Aurora A mutants. The inhibitor furthermore does not induce Aurora B specific effects in cells.

NOVEL BENZIMIDAZOLE DERIVATIVE AND USE THEREOF

The present invention aims to provide a compound capable of inhibiting PCA-1 that can be a target for a novel treatment method of various diseases, and pharmaceutical use of the compound. A compound represented by the formula (I): wherein each symbol is a

Design and synthesis of prostate cancer antigen-1 (PCA-1/ALKBH3) inhibitors as anti-prostate cancer drugs

A series of 1-aryl-3,4-substituted-1H-pyrazol-5-ol derivatives was synthesized and evaluated as prostate cancer antigen-1 (PCA-1/ALKBH3) inhibitors to obtain a novel anti-prostate cancer drug. After modifying 1-(1H-benzimidazol-2-yl)-3,4-dimethyl-1H-pyrazol-5-ol (1), a hit compound found during random screening using a recombinant PCA-1/ALKBH3, 1-(1H-5- methylbenzimidazol-2-yl)-4-benzyl-3-methyl-1H-pyrazol-5-ol (35, HUHS015), was obtained as a potent PCA-1/ALKBH3 inhibitor both in vitro and in vivo. The bioavailability (BA) of 35 was 7.2% in rats after oral administration. As expected, continuously administering 35 significantly suppressed the growth of DU145 cells, which are human hormone-independent prostate cancer cells, in a mouse xenograft model without untoward effects.

Chiral 2-aminobenzimidazoles as recoverable organocatalysts for the addition of 1,3-dicarbonyl compounds to nitroalkenes

(Chemical Equation Presented) Chiral trans-cyclohexanediamine-benzimidazole organocatalysts promote the conjugate addition of a wide variety of 1,3-dicarbonyl compounds such as malonates, ketoesters, and 1,3-diketones to nitroolefins in the presence of TF

BENZIMIDAZOLES WITH A HETERO SPIRO-DECANE RESIDUE AS NPY-Y5 ANTAGONISTS

The present invention relates to compounds of formula (I), or a pharmaceutically acceptable salts, solvates, stereoisomers thereof, formula (I), R1 may be C1-C4 alkyl, aryl or heteroaryl, which may be substituted by one or more: halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, cyano; R2 may be halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, cyano, nitro; or aryl, heteroaryl or heterocycle, which may be substituted by one or more: halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, cyano; or R2 may correspond to -0-R3; R3 is a 6-membered aromatic carbocyclic ring which may contain 1 or 2 nitrogen X is carbon or oxygen; Z is carbon or nitrogen; G is a fused 6-membered aromatic carbocyclic ring which may contain 1 or 2 nitrogen; m may be 0 or an integer ranging from 1 to 4; processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as NPY- Y5 receptor antagonists.

Synthesis, potent anti-staphylococcal activity and QSARs of some novel 2-anilinobenzazoles

Synthesis and anti-staphylococcal activity of a number of substituted 2-anilinobenzimidazoles, benzothiazoles and benzoxazoles are reported. The anti-staphylococcal activities were evaluated in standard in vitro MIC assay method. While anilinobenzimidazole derivatives 11-45 showed very potent anti-staphylococcal activities (greatest activity with an MIC value of 0.095 μg/mL), none of the 2-anilinobenzothiazoles and benzoxazole derivatives exhibited inhibitory activity. QSAR analysis of the anilinobenzimidazoles was studied on the relationship between the anti-staphylococcal activity (MIC in μg/ml) and extrapolated log kw values.

Design, syntheses, and structure-activity relationships of novel NPY Y5 receptor antagonists: 2-{3-Oxospiro[isobenzofuran-1(3H),4′-piperidin]-1′-yl}benzimidazole derivatives

Design, syntheses, and structure-activity relationships of a novel class of 2-{3-oxospiro[isobenzofuran-1(3H),4′-piperidin]-1′-yl}benzimidazole NPY Y5 receptor antagonists are described. The benzimidazole structures were newly designed based on the urea linkage of our prototype Y5 receptor antagonists (2 and 3). By optimizing substituents on the benzimidazole core part of the lead compound 5a, we were able to develop a potent, orally available, and brain-penetrable Y5 selective antagonist (5k). Crown Copyright

Design of potent, orally available antagonists of the transient receptor potential vanilloid 1. Structure-activity relationships of 2-piperazin-1-yl-1H- benzimidazoles

The vanilloid receptor-1 (VR1 or TRPV1) is a membrane-bound, nonselective cation channel that is predominantly expressed by peripheral neurons sensing painful stimuli. TRPV1 antagonists produce antihyperalgesic effects in animal models of inflammatory and neuropathic pain. Herein, we describe the synthesis and the structure-activity relationships of a series of 2-(4-pyridin-2- ylpiperazin-1-yl)-1H-benzo-[d]imidazoles as novel TRPV1 antagonists. Compound 46ad was among the most potent analogues in this series. This compound was orally bioavailable in rats and was efficacious in blocking capsaicin-induced flinch in rats in a dose-dependent manner. Compound 46ad also reversed thermal hyperalgesia in a model of inflammatory pain, which was induced by complete Freund's adjuvant (CFA).